Compare Boston Scientific Corporation (BSX) vs Synopsys, Inc. (SNPS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Scientific Corporation vs Synopsys, Inc. — how do they compare? Boston Scientific Corporation trades at $51.07 (market cap $74.19B), while Synopsys, Inc. trades at $410.7 (market cap $78.68B). The key difference: Boston Scientific Corporation and Synopsys, Inc. are close in size by market cap. Which is the better fit depends on your goals.
| BSX | SNPS | |
|---|---|---|
Market Cap | $74.19B | $78.68B |
Sector | Health | Technology |
52-Week High | $108.14 | $625.80 |
52-Week Low | $42.63 | $372.33 |
Enterprise Value | $86.27B | $87.04B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →About Synopsys, Inc.
Synopsys is a provider of electronic design automation software, intellectual property, and software integrity products. EDA software automates the chip design process, enhancing design accuracy, productivity, and complexity in a full-flow end-to-end solution. The firm's growing SI business allows customers to continuously manage and test the code base for security and quality. Synopsys' comprehensive portfolio is benefiting from a mutual convergence of semiconductor companies moving up-stack toward systems-like companies, and systems companies moving down-stack toward in-house chip design. The resulting expansion in EDA customers alongside secular digitalization of various end markets benefits EDA vendors like Synopsys.
Read more on SNPS →
